Clinical trial • Phase II • Endocrinology

EXENATIDE for Gestational diabetes

Phase II trial of EXENATIDE for Gestational diabetes. 24 participants.

Overview

Trial Therapeutic Area
Endocrinology
Trial Disease
Gestational diabetes
Trial Stage
Phase II
Drug Modality
Peptide/protein/enzyme|Radiopharmaceutical

Key dates

Initial CTIS Submission Date
20-12-2024
First CTIS Authorization Date
13-01-2025

Trial design

Phase II trial across 1 site in Netherlands.

Target Sample Size
24

Eligibility

Recruits 24 Vulnerable population not selected (isVulnerablePopulationSelected: false). Participants must provide signed informed consent (inclusion: "Signed informed consent"; exclusion: "no signed informed consent"). Minors are excluded (exclusion: "Age < 18 years"). No assent process described..

Pregnancy Exclusion
Current pregnancy or the wish to become pregnant within 6 months
Vulnerable Population
Vulnerable population not selected (isVulnerablePopulationSelected: false). Participants must provide signed informed consent (inclusion: "Signed informed consent"; exclusion: "no signed informed consent"). Minors are excluded (exclusion: "Age < 18 years"). No assent process described.

Inclusion criteria

  • {"criterion_text":"- Pregnancy with diagnosis of GDM, within the last 5 years"}
  • {"criterion_text":"- No other previous pregnancies"}
  • {"criterion_text":"- Complete resolution of GDM after delivery (HbAlc in normal range, fasting glucose < 1OO mg/dl for at least I year in the absence of active pharmacologic therapy or ongoing procedures)"}
  • {"criterion_text":"- Signed informed consent"}

Exclusion criteria

  • {"criterion_text":"- Previous treatment (within 6 months) with synthetic Exendin (Exenatide, Byetta@) or Dipeptidyl-Peptidase IV inhibitors"}
  • {"criterion_text":"- Breast feeding"}
  • {"criterion_text":"- Current pregnancy or the wish to become pregnant within 6 months"}
  • {"criterion_text":"- Renal dysfunction (Calculated creatinine clearance below 40 ml/min)"}
  • {"criterion_text":"- Liver disease defined as aspartate aminotransferase or alan¡ne aminotransferase level of more than three times the upper limit of normal range"}
  • {"criterion_text":"- Age < 18 years"}
  • {"criterion_text":"- incapacitated"}
  • {"criterion_text":"- no signed informed consent"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- The main parameter of the study is the quantitative assessment of pancreatic 68Ga-NODAGA-exendin-4 uptake women with and without a history of GDM by PET/CT.","definition_or_measurement_approach":"Quantitative assessment of 68Ga-NODAGA-exendin-4 tracer accumulation in the pancreas by PET/CT imaging (quantitative analysis of PET images)."}

Secondary endpoints

  • {"endpoint_text":"- The correlation between Ga-exendin tracer accumulation and beta cell function of the subjects","definition_or_measurement_approach":"Correlation between tracer accumulation (PET imaging) and beta cell function as assessed by oral glucose tolerance testing (OGTT)."}

Recruitment

Planned Sample Size
24
Recruitment Window Months
12
Consent Approach
Signed informed consent is required (inclusion criterion: "Signed informed consent"). Separate subject information and informed consent forms exist for women with and without GDM (documents: L1_SIS_ICF_women_with_GDM; L1_SIS_ICF_women_without_GDM). No assent process or age-specific consent procedures described. Language availability not specified (trial translations include Dutch).

Geography

Total Number Of Sites
1
Total Number Of Participants
24

Netherlands

Earliest CTIS Part Ii Submission Date
09-01-2025
Latest Decision Or Authorization Date
13-01-2025
Processing Time Days
4
Number Of Sites
1
Number Of Participants
24

Sites

Site Name
Radboud universitair medisch centrum Stichting
Department Name
Nuclear Medicine
Contact Person Name
Martin Gotthardt
Contact Person Email
martin.gotthardt@radboudumc.nl

Sponsor

Primary sponsor

Full Name
Radboud universitair medisch centrum Stichting
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Netherlands

Investigational products

Investigational Product Name
EXENATIDE
Active Substance
EXENATIDE
Modality
Peptide/protein/enzyme|Radiopharmaceutical
Routes Of Administration
INTRAVENOUS BOLUS INJECTION/IV INFUSION
Route
INTRAVENOUS BOLUS INJECTION/IV INFUSION
Authorisation Status
marketingAuthNumber: -; prodAuthStatus: 2
Maximum Dose
150 MBq

Related trials

Other published trials that may interest you.